We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
WAT beat Q4 estimates with EPS up 10.5% and sales rising 7% year over year.
Pharma and Industrial sales rose 8%, while Europe revenues climbed 13% reported.
WAT guides 2026 EPS to $14.30-$14.50 on 5.5-7% constant currency sales growth.
Waters Corporation (WAT - Free Report) reported fourth-quarter 2025 non-GAAP earnings of $4.53 per share, which beat the Zacks Consensus Estimate by 0.67% and increased 10.5% year over year.
Net sales of $932.4 million topped the Zacks Consensus Estimate by 0.55%. The figure increased by 7% on a reported basis and 6% on a constant currency (cc) basis year over year.
Waters’ Q4 Top Line in Detail
WAT operates under two organized segments: Waters and TA. The Waters segment generated sales worth $823.9 million, up 8% on a reported basis and 7% on a cc basis, year over year. Sales in the TA segment were $108.4 million, flat year over year on both a reported and cc basis.
Products & Services: The division comprises three segments: Instruments, Services and Chemistry. Instrument sales were $432.9 million, up 3% year over year on a reported and cc basis. Services sales were $329.1 million, which increased 9% year over year on a reported basis and 8% at cc. Chemistry sales were $170.3 million, which grew 13% on a reported basis and 12% at cc, year over year. The Services and Chemistry segments jointly generated recurring revenues of $499.5 million, up 10% year over year on a reported basis and 9% at cc.
Waters Corporation Price, Consensus and EPS Surprise
Waters serves three end markets: Pharmaceutical, Industrial, and Governmental & Academic. The Pharmaceutical market generated sales of $540.6 million, which increased 8% on a year-over-year basis, reportedly, and 7% at cc. Industrial sales were $284.5 million, up 8% year over year on a reported and cc basis. Government & Academic sales decreased 2% reportedly and 3% at cc to $107.3 million.
Waters’ operating regions include Asia, the Americas and Europe. Asia generated sales of $283.9 million, up 4% and 11% on a reported and cc basis, respectively. Americas sales were $332.4 million, which increased 4% in both reported and cc terms. Europe generated sales of $315.9 million, which increased 13% reportedly and 4% at cc.
WAT’s Q4 Operating Details
In the fourth quarter of 2025, non-GAAP selling and administrative expenses were $191 million, up 13.3% year over year. As a percentage of net sales, the figure increased 120 basis points (bps) on a year-over-year basis.
Research and development expenses of $50.1 million, up 8.3% year over year. As a percentage of net sales, the figure expanded 10 bps year over year.
The adjusted operating margin was 35.2%, which contracted 20 bps year over year.
Waters Balance Sheet & Cash Flow
As of Dec. 31, 2025, cash and cash equivalents were $587.8 million, up from $459.1 million as of Sept. 27.
Waters generated cash from operations of $164.5 million in the reported quarter. The company reported a free cash flow of $125.2 million.
WAT Offers Q126 and FY26 Guidance
Waters expects first-quarter sales growth between 7% and 9% on a cc basis. Sales on an organic reported basis and reported basis are expected to be in the range of $718-$731 million and $1.19 billion to $1.21 billion, respectively.
Waters expects first-quarter 2026 non-GAAP earnings to be in the range of $2.25-$2.35 per share. This indicates year-over-year growth of approximately 0.0% to 4.4%.
For full-year 2026, Waters expects cc sales growth between 5.5% and 7%. Sales on an organic reported basis and reported basis are expected to be in the range of $3.35-$3.40 billion and $6.40 billion to $6.45 billion, respectively.
Waters expects non-GAAP earnings in the $14.30 to $14.50 per share range. This reflects year-over-year growth of approximately 8.9% to 10.4%.
AngioDynamics shares have increased 4.8% in the trailing 12-month period. The company is scheduled to release third-quarter 2026 results on April 1. ANGO sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes shares have dropped 7.5% in the trailing 12-month period. ALKS is scheduled to release fourth-quarter 2025 results on Feb. 25. Alkermes sports a Zacks Rank #1.
Ironwood Pharmaceuticals has returned 129.4% in the trailing 12-month period. IRWD is set to report its fourth-quarter 2025 results on Feb. 26. The company currently sports a Zacks Rank #1.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Waters Q4 Earnings Surpass Estimates, Revenues Increase Y/Y
Key Takeaways
Waters Corporation (WAT - Free Report) reported fourth-quarter 2025 non-GAAP earnings of $4.53 per share, which beat the Zacks Consensus Estimate by 0.67% and increased 10.5% year over year.
Net sales of $932.4 million topped the Zacks Consensus Estimate by 0.55%. The figure increased by 7% on a reported basis and 6% on a constant currency (cc) basis year over year.
Waters’ Q4 Top Line in Detail
WAT operates under two organized segments: Waters and TA. The Waters segment generated sales worth $823.9 million, up 8% on a reported basis and 7% on a cc basis, year over year. Sales in the TA segment were $108.4 million, flat year over year on both a reported and cc basis.
Products & Services: The division comprises three segments: Instruments, Services and Chemistry. Instrument sales were $432.9 million, up 3% year over year on a reported and cc basis. Services sales were $329.1 million, which increased 9% year over year on a reported basis and 8% at cc. Chemistry sales were $170.3 million, which grew 13% on a reported basis and 12% at cc, year over year. The Services and Chemistry segments jointly generated recurring revenues of $499.5 million, up 10% year over year on a reported basis and 9% at cc.
Waters Corporation Price, Consensus and EPS Surprise
Waters Corporation price-consensus-eps-surprise-chart | Waters Corporation Quote
Waters serves three end markets: Pharmaceutical, Industrial, and Governmental & Academic. The Pharmaceutical market generated sales of $540.6 million, which increased 8% on a year-over-year basis, reportedly, and 7% at cc. Industrial sales were $284.5 million, up 8% year over year on a reported and cc basis. Government & Academic sales decreased 2% reportedly and 3% at cc to $107.3 million.
Waters’ operating regions include Asia, the Americas and Europe. Asia generated sales of $283.9 million, up 4% and 11% on a reported and cc basis, respectively. Americas sales were $332.4 million, which increased 4% in both reported and cc terms. Europe generated sales of $315.9 million, which increased 13% reportedly and 4% at cc.
WAT’s Q4 Operating Details
In the fourth quarter of 2025, non-GAAP selling and administrative expenses were $191 million, up 13.3% year over year. As a percentage of net sales, the figure increased 120 basis points (bps) on a year-over-year basis.
Research and development expenses of $50.1 million, up 8.3% year over year. As a percentage of net sales, the figure expanded 10 bps year over year.
The adjusted operating margin was 35.2%, which contracted 20 bps year over year.
Waters Balance Sheet & Cash Flow
As of Dec. 31, 2025, cash and cash equivalents were $587.8 million, up from $459.1 million as of Sept. 27.
Waters generated cash from operations of $164.5 million in the reported quarter. The company reported a free cash flow of $125.2 million.
WAT Offers Q126 and FY26 Guidance
Waters expects first-quarter sales growth between 7% and 9% on a cc basis. Sales on an organic reported basis and reported basis are expected to be in the range of $718-$731 million and $1.19 billion to $1.21 billion, respectively.
Waters expects first-quarter 2026 non-GAAP earnings to be in the range of $2.25-$2.35 per share. This indicates year-over-year growth of approximately 0.0% to 4.4%.
For full-year 2026, Waters expects cc sales growth between 5.5% and 7%. Sales on an organic reported basis and reported basis are expected to be in the range of $3.35-$3.40 billion and $6.40 billion to $6.45 billion, respectively.
Waters expects non-GAAP earnings in the $14.30 to $14.50 per share range. This reflects year-over-year growth of approximately 8.9% to 10.4%.
Zacks Rank & Other Stocks to Consider
Currently, Waters carries a Zacks Rank #2 (Buy).
AngioDynamics (ANGO - Free Report) , Alkermes (ALKS - Free Report) and Ironwood Pharmaceuticals (IRWD - Free Report) are some other better-ranked stocks that investors can consider in the broader Zacks Medical sector.
AngioDynamics shares have increased 4.8% in the trailing 12-month period. The company is scheduled to release third-quarter 2026 results on April 1. ANGO sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes shares have dropped 7.5% in the trailing 12-month period. ALKS is scheduled to release fourth-quarter 2025 results on Feb. 25. Alkermes sports a Zacks Rank #1.
Ironwood Pharmaceuticals has returned 129.4% in the trailing 12-month period. IRWD is set to report its fourth-quarter 2025 results on Feb. 26. The company currently sports a Zacks Rank #1.